You are receiving this email because you signed up to receive email updates from UK Investment Guides. If you do not want to receive these emails anymore, please unsubscribe.

Frontier Diagnostics

‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Early-stage oncology innovation. HMRC approved EIS. Up to 10.5X returns projected.

At Frontier Diagnostics, we are not just developing new ways to detect cancer we are changing the entire timeline of how it's treated. Led by industry-renowned biochemist Dr. Martin Burow our team has pioneered a non-invasive liquid biopsy that identifies cancer earlier than traditional methods—before symptoms appear and long before imaging can detect changes. Through a simple blood test, we provide real-time monitoring, personalised treatment guidance, and peace of mind for patients. Why Invest?

Rising global demand for fast, personalised cancer care Proprietary technology with CTC-based diagnostics

In-clinic results in 5 minutes via our proprietary methods

Active expansion in the Europe and Southeast Asia Projected £125M valuation by 2029, with forecasted 10.5X return

Enterprise Investment Scheme (EIS) Benefits